Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3986 - Effect of a combined treatment with iPS cells derived dendritic cells and proton beam irradiation in a murine subcutaneous melanoma model

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Yuzi Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

Y. Wang1, L. Sun1, X. Li2, K. Tsuboi1

Author affiliations

  • 1 Proton Medical Research Center, University of Tsukuba, 305-8577 - Tsukuba, ibaraki/JP
  • 2 Division Of The Transplantation Immunology, National Research Institute for Child Health and Development, 157-8535 - Tokyo/JP
More

Resources

Abstract 3986

Background

In situ dying and just died tumor cells after irradiation give danger signals and release tumor-specific antigens which are sequentially incorporated into dendritic cells (DCs). Our previous studies on a murine subcutaneous tumor model showed that injection of bone marrow derived DCs (BM-DCs) after X-ray therapy significantly delayed tumor growth. As compared to X-rays, the unique biological and physical benefits of proton beam therapy may prove superior in the systemic immune effect. In addition, usage of DCs induced from iPS cells (iPS-DCs) may overcome practical problems of BM-DCs such as a limited number of applicable cells and an induction period of 7 days. The purpose of this study is to investigate: 1) whether proton beam therapy are superior in induction of anti-tumor immune response compared to X-ray therapy. 2) whether the function of induced iPS-DCs is superior to that of BM-DCs.

Methods

DCs were induced by using GM-CSF and IL-4 from autologous bone marrow cells or iPS cells of C57BL/6 mice. Syngeneic B16 melanoma cells subcutaneously implanted at the thighs of C57BL/6 mice were treated with X-ray or proton beam 5 days after inoculation. After 1, 3, 5, 7 days from irradiation, induced BM-DCs or iPS-DCs were injected directly into the tumor site. Tumor growth was monitored, and survival analyses were performed.

Results

Proton beam therapy induced superior immunogenicity of cancer cell comparing to X-ray therapy. Also, iPS-DCs showed an excellent ability to incorporate antigens in vitro comparing to BM-DCs. The combination treatment of proton beam and iPS-DCs significantly delayed tumor growth in vivo.

Conclusions

iPS-DCs should overcome the practical problems of BM-DCs in cancer treatment. The combination therapy of proton beam and iPS-DCs administration can offer a promising novel cancer therapy.

Clinical trial identification

Legal entity responsible for the study

Koji Tsuboi.

Funding

Japan Society for the Promotion of Science.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings